Aims: EGFR and ALK analysis is routinely undertaken prior to targeted treatment of non-squamous non-small cell lung carcinoma (NSCLC). Increasingly limited resources require molecular pathology services to be cost effective without detriment to patient care.
INTRODUCTION
Current UK and USA recommendations for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (non-squamous NSCLC) include first line EGFR tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) for tumours with activating EGFR mutations; and ALK inhibitors (crizotinib and ceritinib) for patients whose tumours harbour ALK gene rearrangements. [1] [2] [3] As a result, predictive EGFR mutation analysis has been carried out by clinical laboratories since 2009 and in 2013 ALK rearrangement analysis was added to the testing algorithm. Studies have shown that in a Caucasian population approximately 10% of NSCLC have EGFR mutations, 2 to 5% have ALK rearrangements, and 35% have KRAS mutations. Although there is no direct therapeutic value in the detection of somatic KRAS mutations it is performed in many laboratories as KRAS mutations are, in the vast majority of samples, mutually exclusive with EGFR and ALK mutations. 4 Thyroid transcription factor 1 (TTF1) has, for many years, been used as an immunohistochemical marker to aid the diagnosis of lung adenocarcinoma. Approximately 80% of non-squamous NSCLC requested for molecular pathology testing show positive nuclear staining with TTF1 antibodies. 6 Several studies have shown a correlation between TTF1 protein expression and the presence of EGFR mutations (see table 1), indeed TTF1 IHC has been shown to be a good negative predictor of EGFR mutations in western populations; however, this association appears to be less strong in East Asian populations. 
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DISCUSSION
In our cohort TTF1 IHC had a high negative predictive value (NPV) for EGFR mutations supporting the association previously reported in several studies with Caucasian populations, 6 7 9 12 although this correlation seems to be weaker in East Asian populations. 13 15-17 Two studies used a scoring system to determine TTF1 status which may have reduced the number of positive samples and therefore lowered the NPV. 7 16 Our study was carried out in a clinical diagnostic setting and any nuclear staining, even focal staining, was considered positive for TTF1. One sample from a total of 118 EGFR mutation positive patients showed only cytoplasmic staining with the TTF1 antibody; upon further investigation this biopsy, which had a p.(Gly719X) EGFR mutation, was taken post chemo-radiation. A previous specimen taken pretreatment was TTF1 positive, however since several years had elapsed between the two samples it was not possible to determine if the latter biopsy was a recurrence or a second primary tumour. Unfortunately, there was too little tissue remaining in the pretreatment sample to perform EGFR mutation analysis.
Many clinical laboratories are experiencing increasing pressures to reduce costs; where funding is restricted algorithms must supply the most cost effective use of limited resources without compromising clinical utility and the welfare of patients. The saving represented by only testing patients eligible for treatment with targeted therapies (the request model) would be easily achievable in most clinical laboratories without any detrimental effect on patient care; a proposal supported by data from another institution. 18 In reality NHS Lothian employs a system between the reflex and request models and accepts requests from oncologists if a patient is being considered for treatment or from histopathologists if the diagnostic sample confirms distant metastatic disease.
Currently there is no direct therapeutic impact of KRAS nevertheless KRAS mutation status in non-squamous NSCLC does have some value, since a large proportion of tumours carry mutations their detection ensures, particularly in samples with a low proportion of neoplastic cells, that the appropriate tissue has been tested. Withdrawing KRAS analysis would reduce costs by 18% compared to the reflex model. However, stratifying the cohort using the serial model, including KRAS analysis, would allow a much greater saving; a 32.7% reduction compared to the reflex model. Recent European Society for Medical Oncology (ESMO) guidelines do not recommend KRAS mutation analysis in a serial model due to the effect on turnaround times and the potential waste of tumour material. 19 However KRAS mutation analysis can be performed in less than a day and in our lab is already frequently available before performing EGFR analysis. On average lung cancer molecular pathology testing in NHS Lothian is reported in 3.8 working days; the addition of an extra day for KRAS mutation analysis would have little impact on patient treatment and falls well within the 10 working days recommended by the joint guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 1 Where specimen size, and therefore DNA yield, is limiting samples should proceed straight to EGFR analysis to avoid the risk of exhausting the sample. Laboratories whose primary method is a multiplex assay, for example next generation sequencing (NGS), would not benefit from the serial model; but for many labs NGS is not an option and will, for the foreseeable future, continue to carry out single genes analyses.
The value of TTF1 IHC may not be limited to cost efficiency, if an initial specimen was considered insufficient for molecular analysis the TTF1 status may help determine the value of subjecting a patient to a procedure to obtain a repeat sample. Although promising there is, as yet, too little data on the association between TTF1 IHC and EGFR to fully support its use as a negative predictor for EGFR mutations. Further audits by molecular pathology laboratories could elucidate this relationship and help confirm or refute the use of this readily available histopathology biomarker as a screening tool prior to EGFR mutation analysis.
